Advancements in Oral Cancer Therapy: The Role of Botanical Compounds in Tumor Management
The landscape of oral and oropharyngeal cancer treatment is evolving, with new research highlighting the potential of botanical drug candidates to complement traditional oncology protocols. A recent Phase I clinical trial led by the UCLA Jonsson Comprehensive Cancer Center has revealed promising data regarding APG-157, a plant-based drug that targets the inflammatory and microbial environment of oral tumors.
At CJ Henley, DMD, our involvement in the Baptist MD Anderson Head and Neck Tumor Board allows us to integrate these emerging clinical insights into our specialized care for patients navigating cancer treatment.
The Science Behind APG-157: Curcumin and Inflammation
APG-157 is a botanical drug composed of multiple plant-derived compounds, most notably curcumin. The clinical trial demonstrated that when taken orally, high concentrations of curcumin and its metabolic byproducts are absorbed by tumor tissues in as little as three hours.
The significance of this absorption lies in its effect on cytokines—the proteins responsible for driving inflammation within the body. By reducing cytokine concentrations in the saliva, APG-157 may help modulate the inflammatory "microenvironment" that allows tumors to thrive.
Microbiome Modulation and Gram-Negative Bacteria
Beyond inflammation, this therapy addresses the oral microbiome. Researchers found that APG-157 reduced the relative abundance of Bacteroides species, a group of gram-negative bacteria.
Gram-negative bacteria possess a protective outer layer that effectively "hides" them from the immune system. In the context of oral health, an overabundance of these bacteria is closely correlated with the development and progression of oral cancers. Reducing these bacterial populations is a critical step in restoring a healthy oral environment during and after cancer therapy.
A Medically-Informed Approach to Oncology Dental Care
As a practice focused on Complex & Medically Involved Care, we understand that oral cancer treatment requires more than routine dentistry. It requires a deep understanding of how systemic therapies and the oral microbiome interact.
We prioritize a two-hour comprehensive evaluation for our oncology patients to discuss these emerging therapies, manage side effects like xerostomia, and coordinate care with your medical team to ensure the best possible long-term outcomes.
Reviewed and Updated February 2026